The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non–small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B.
 
Tatsuro Fukuhara
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb Japan (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst)
 
Hiromi Nagashima
No Relationships to Disclose
 
Yu Utsumi
No Relationships to Disclose
 
Aya Suzuki
No Relationships to Disclose
 
Masahiro Seike
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo Company; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Taiho Pharmaceutical
 
Akihiko Miyanaga
No Relationships to Disclose
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Akira Kisohara
No Relationships to Disclose
 
Yosuke Kawashima
No Relationships to Disclose
 
Hajime Asahina
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca
 
Hisashi Tanaka
No Relationships to Disclose
 
Ryota Kanemaru
No Relationships to Disclose
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo KK; Lilly; Merck
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Haruna Sato
No Relationships to Disclose
 
Kazuko Sakai
Honoraria - Chugai Pharma; Hitachi; Life Technologies; Takeda; YODOSHA
 
Kazuto Nishio
Speakers' Bureau - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; DAIICHI SANKYO; Fujirebio; Guardant Health; Janssen; Lilly Japan; Merck; MSD K.K.; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; SymBio Pharmaceuticals; Takeda; Yakult Honsha
Research Funding - Hitachi Chemical; Lilly Japan; Nichirei; Nippon Boehringer Ingelheim; Osaka Minami Hospital; Otsuka; SYSMEX; West Japan Oncology Group
 
Fumiaki Takahashi
No Relationships to Disclose
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca; Takeda
 
Makoto Maemondo
Honoraria - AstraZeneca/Hong Kong; Boehringer Ingelheim; Chugai Pharma
Research Funding - Boehringer Ingelheim